Theresa M. Thole

  • Citations Per Year
Learn More
The systemic and resistant nature of metastatic neuroblastoma renders it largely incurable with current multimodal treatment. Clinical progression stems mainly from the increasing burden of metastatic colonization. Therapeutically inhibiting the migration-invasion-metastasis cascade would be of great benefit, but the mechanisms driving this cycle are as yet(More)
Neuroblastoma is an embryonic solid tumor of neural crest origin and accounts for 11% of all cancer-related deaths in children. Novel therapeutic strategies are therefore urgently required. MYCN oncogene amplification, which occurs in 20% of neuroblastomas, is a hallmark of high risk. Here, we aimed to exploit molecular mechanisms that can be(More)
The number of long-term survivors of high-risk neuroblastoma remains discouraging, with 10-year survival as low as 20%, despite decades of considerable international efforts to improve outcome. Major obstacles remain and include managing resistance to induction therapy, which causes tumor progression and early death in high-risk patients, and managing(More)
Johannes Fabian1,2, Desirée Opitz1, Kristina Althoff3, Marco Lodrini1,4, Barbara Hero5, Ruth Volland5, Anneleen Beckers6,7, Katleen de Preter6,7, Anneleen Decock6,7, Nitin Patil8, Mohammed Abba8, Annette Kopp-Schneider9, Kathy Astrahantseff4, Jasmin Wünschel1,4, Sebastian Pfeil4, Maria Ercu4, Annette Künkele4, Jamie Hu1,10, Theresa Thole1,4, Leonille(More)
Neuroblastoma is an embryonic solid tumor of neural crest origin and accounts for 11% of all cancer-related deaths in children. Novel therapeutic strategies are therefore urgently required. MYCN oncogene amplification, which occurs in 20% of neuroblastomas, is a hallmark of high risk. Here, we aimed to exploit molecular mechanisms that can be(More)
  • 1